Purinergic Signaling in Pulmonary Inflammation.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 17 05 2019
accepted: 01 07 2019
entrez: 6 8 2019
pubmed: 6 8 2019
medline: 21 10 2020
Statut: epublish

Résumé

Purine nucleotides and nucleosides are at the center of biologic reactions. In particular, adenosine triphosphate (ATP) is the fundamental energy currency of cellular activity and adenosine has been demonstrated to play essential roles in human physiology and pathophysiology. In this review, we examine the role of purinergic signaling in acute and chronic pulmonary inflammation, with emphasis on ATP and adenosine. ATP is released into extracellular space in response to cellular injury and necrosis. It is then metabolized to adenosine monophosphate (AMP) via ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and further hydrolyzed to adenosine via ecto-5'-nucleotidase (CD73). Adenosine signals via one of four adenosine receptors to exert pro- or anti-inflammatory effects. Adenosine signaling is terminated by intracellular transport by concentrative or equilibrative nucleoside transporters (CNTs and ENTs), deamination to inosine by adenosine deaminase (ADA), or phosphorylation back into AMP via adenosine kinase (AK). Pulmonary inflammatory and hypoxic conditions lead to increased extracellular ATP, adenosine diphosphate (ADP) and adenosine levels, which translates to increased adenosine signaling. Adenosine signaling is central to the pulmonary injury response, leading to various effects on inflammation, repair and remodeling processes that are either tissue-protective or tissue destructive. In the acute setting, particularly through activation of adenosine 2A and 2B receptors, adenosine signaling serves an anti-inflammatory, tissue-protective role. However, excessive adenosine signaling in the chronic setting promotes pro-inflammatory, tissue destructive effects in chronic pulmonary inflammation.

Identifiants

pubmed: 31379836
doi: 10.3389/fimmu.2019.01633
pmc: PMC6646739
doi:

Substances chimiques

Purinergic Agents 0
Adenosine Monophosphate 415SHH325A
Adenosine Triphosphate 8L70Q75FXE
Adenosine Deaminase EC 3.5.4.4

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1633

Subventions

Organisme : NHLBI NIH HHS
ID : P01 HL114457
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL133900
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM120011
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL109233
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK109574
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL119837
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK097075
Pays : United States

Références

Am J Physiol. 1999 Mar;276(3):C659-66
pubmed: 10069993
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6377-81
pubmed: 10339595
N Engl J Med. 2000 May 4;342(18):1334-49
pubmed: 10793167
J Exp Med. 2000 Jul 17;192(2):159-70
pubmed: 10899903
Clin Immunol. 2001 Jun;99(3):308-19
pubmed: 11358425
Nature. 2001 Dec 20-27;414(6866):916-20
pubmed: 11780065
J Lab Clin Med. 2002 Aug;140(2):84-91
pubmed: 12228764
J Clin Invest. 2002 Oct;110(7):993-1002
pubmed: 12370277
Eur Respir J. 2002 Dec;20(6):1393-8
pubmed: 12503694
Trends Pharmacol Sci. 2003 Feb;24(2):66-70
pubmed: 12559769
J Clin Invest. 2003 Feb;111(3):291-7
pubmed: 12569150
Annu Rev Med. 2004;55:395-417
pubmed: 14746528
Annu Rev Immunol. 2004;22:657-82
pubmed: 15032592
Blood. 2004 Dec 15;104(13):3986-92
pubmed: 15319286
Am J Respir Cell Mol Biol. 2005 Jan;32(1):2-8
pubmed: 15472138
J Exp Med. 2004 Dec 6;200(11):1395-405
pubmed: 15583013
Adv Immunol. 2005;86:1-41
pubmed: 15705418
Am J Physiol Lung Cell Mol Physiol. 2005 Sep;289(3):L489-96
pubmed: 15908478
J Immunol. 2005 Aug 1;175(3):1937-46
pubmed: 16034138
N Engl J Med. 2005 Oct 20;353(16):1685-93
pubmed: 16236739
J Exp Med. 2005 Dec 5;202(11):1493-505
pubmed: 16330813
Pharmacol Rev. 2006 Mar;58(1):58-86
pubmed: 16507883
J Immunol. 2006 Apr 1;176(7):4449-58
pubmed: 16547283
Blood. 2006 Sep 1;108(5):1602-10
pubmed: 16670267
J Clin Invest. 2006 May;116(5):1274-83
pubmed: 16670768
J Clin Invest. 2006 Aug;116(8):2173-2182
pubmed: 16841096
J Physiol. 1929 Nov 25;68(3):213-37
pubmed: 16994064
Circ Res. 2006 Nov 10;99(10):1100-8
pubmed: 17038639
FASEB J. 2006 Nov;20(13):2242-50
pubmed: 17077301
Arterioscler Thromb Vasc Biol. 2007 May;27(5):1004-13
pubmed: 17332491
Circulation. 2007 Mar 27;115(12):1581-90
pubmed: 17353435
Cell Death Differ. 2007 Jul;14(7):1315-23
pubmed: 17396131
PLoS One. 2007 May 30;2(5):e482
pubmed: 17534432
J Immunol. 2007 Jun 15;178(12):8127-37
pubmed: 17548651
Nat Med. 2007 Aug;13(8):913-9
pubmed: 17632526
Circulation. 2007 Oct 16;116(16):1784-94
pubmed: 17909107
Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L319-24
pubmed: 17993588
Blood. 2008 Jun 15;111(12):5571-80
pubmed: 18309031
Trends Cardiovasc Med. 2008 Apr;18(3):103-7
pubmed: 18436149
Circulation. 2008 Jul 8;118(2):166-75
pubmed: 18591435
PLoS One. 2008 Jul 30;3(7):e2801
pubmed: 18665255
N Engl J Med. 2008 Sep 18;359(12):1238-51
pubmed: 18753638
Nat Rev Drug Discov. 2008 Sep;7(9):759-70
pubmed: 18758473
J Clin Invest. 2008 Oct;118(10):3301-15
pubmed: 18787641
Gastroenterology. 2008 Nov;135(5):1739-1750.e3
pubmed: 18804111
Blood. 2009 Jan 1;113(1):224-32
pubmed: 18812468
FASEB J. 2009 Feb;23(2):473-82
pubmed: 18838482
Respir Res. 2008 Dec 13;9:79
pubmed: 19077288
Gastroenterology. 2009 Feb;136(2):607-18
pubmed: 19105964
Nat Immunol. 2009 Feb;10(2):195-202
pubmed: 19122655
N Engl J Med. 2009 Jan 29;360(5):447-58
pubmed: 19179314
Exp Hematol. 2009 May;37(5):533-8
pubmed: 19375644
Pharmacol Ther. 2009 Jul;123(1):105-16
pubmed: 19426761
N Engl J Med. 2009 May 21;360(21):2191-201
pubmed: 19458364
Curr Opin Pharmacol. 2009 Aug;9(4):501-6
pubmed: 19539527
Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10684-9
pubmed: 19541651
Am J Respir Cell Mol Biol. 2010 May;42(5):564-71
pubmed: 19556606
Respir Res. 2009 Jun 26;10:58
pubmed: 19558673
Eur J Pharmacol. 2009 Oct 1;619(1-3):92-6
pubmed: 19654006
PLoS One. 2009 Aug 26;4(8):e6784
pubmed: 19707555
FASEB J. 2010 Jan;24(1):70-80
pubmed: 19720619
Anesthesiology. 2009 Oct;111(4):904-15
pubmed: 19741501
Trends Pharmacol Sci. 2009 Oct;30(10):528-35
pubmed: 19762093
Cell Death Differ. 2010 Jul;17(7):1071-82
pubmed: 19763139
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16788-93
pubmed: 19805374
Physiology (Bethesda). 2009 Oct;24:298-306
pubmed: 19815856
J Immunol. 2009 Dec 1;183(11):7602-10
pubmed: 19917691
Am J Respir Crit Care Med. 2010 May 1;181(9):928-34
pubmed: 20093639
PLoS One. 2010 Feb 16;5(2):e9224
pubmed: 20169073
J Immunol. 2010 Apr 1;184(7):4017-24
pubmed: 20207994
Am J Physiol Lung Cell Mol Physiol. 2010 Jun;298(6):L755-67
pubmed: 20228181
Ophthalmology. 2010 Jul;117(7):1287-93
pubmed: 20304499
J Immunol. 2010 May 1;184(9):5271-9
pubmed: 20348420
Am J Respir Crit Care Med. 2010 Sep 15;182(6):774-83
pubmed: 20522787
Iran J Allergy Asthma Immunol. 2010 Mar;9(1):7-12
pubmed: 20548128
Blood. 2010 Dec 2;116(23):5010-20
pubmed: 20798237
Nat Med. 2010 Dec;16(12):1434-8
pubmed: 21102458
J Immunol. 2011 Jan 15;186(2):1097-106
pubmed: 21149612
Blood. 2011 Feb 24;117(8):2548-55
pubmed: 21173118
J Cell Sci. 2011 Feb 15;124(Pt 4):657-68
pubmed: 21266468
N Engl J Med. 2011 Feb 3;364(5):432-42
pubmed: 21288095
Pharmacol Rev. 2011 Mar;63(1):1-34
pubmed: 21303899
Chest. 2011 Oct;140(4):954-960
pubmed: 21454402
J Clin Invest. 1990 Apr;85(4):1150-7
pubmed: 2156895
PLoS One. 2011;6(7):e22667
pubmed: 21799929
Annu Rev Physiol. 2012;74:153-75
pubmed: 21942704
Immunity. 2011 Oct 28;35(4):445-55
pubmed: 22035837
Nat Med. 2011 Nov 07;17(11):1391-401
pubmed: 22064429
J Clin Invest. 2012 Feb;122(2):693-710
pubmed: 22269324
Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):870-8
pubmed: 22423039
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
N Engl J Med. 2012 Dec 13;367(24):2322-33
pubmed: 23234515
J Mol Med (Berl). 2013 Feb;91(2):141-6
pubmed: 23338058
J Mol Med (Berl). 2013 Feb;91(2):173-81
pubmed: 23340998
Am J Respir Cell Mol Biol. 2013 May;48(5):601-9
pubmed: 23349052
FASEB J. 2013 Jun;27(6):2207-19
pubmed: 23413361
Ann Thorac Surg. 2013 May;95(5):1762-7
pubmed: 23541429
Purinergic Signal. 2013 Sep;9(3):427-32
pubmed: 23584760
Am J Respir Cell Mol Biol. 2013 Aug;49(2):296-305
pubmed: 23590299
FASEB J. 2013 Aug;27(8):3078-89
pubmed: 23603835
Cell Signal. 2013 Sep;25(9):1913-23
pubmed: 23712033
MBio. 2013 Jul 23;4(4):null
pubmed: 23882016
Front Cell Neurosci. 2013 Oct 08;7:171
pubmed: 24115920
Anesthesiology. 2013 Dec;119(6):1474-89
pubmed: 24126264
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18351-2
pubmed: 24187149
J Immunol. 2014 Feb 1;192(3):1249-56
pubmed: 24391213
Am J Physiol Lung Cell Mol Physiol. 2014 Mar 15;306(6):L497-507
pubmed: 24414256
Lancet Respir Med. 2014 Feb;2(2):98-107
pubmed: 24503265
PLoS One. 2014 Apr 18;9(4):e95382
pubmed: 24748324
Nature. 2014 May 15;509(7500):310-7
pubmed: 24828189
J Virol. 2014 Sep 1;88(17):10214-27
pubmed: 24965449
J Immunol. 2014 Oct 1;193(7):3755-68
pubmed: 25172494
FASEB J. 2015 Jan;29(1):50-60
pubmed: 25318478
Chest. 2015 Aug;148(2):430-435
pubmed: 25590209
Sci Rep. 2015 Feb 25;5:8610
pubmed: 25712807
Ann Am Thorac Soc. 2015 May;12(5):765-74
pubmed: 25742123
Immunity. 2015 Apr 21;42(4):640-53
pubmed: 25862090
J Immunol. 2015 Aug 15;195(4):1815-24
pubmed: 26188061
Am J Respir Cell Mol Biol. 2016 Apr;54(4):574-83
pubmed: 26414702
Crit Care Med. 2016 Apr;44(4):e181-9
pubmed: 26491864
FASEB J. 2016 Feb;30(2):874-83
pubmed: 26527068
Eur Respir J. 2016 Jan;47(1):254-63
pubmed: 26541524
Cancer Res. 2016 May 15;76(10):3045-56
pubmed: 26921334
Hum Immunol. 2016 Oct;77(10):916-920
pubmed: 27430193
Oncotarget. 2017 May 30;8(22):35962-35972
pubmed: 28415591
J Mol Med (Berl). 2017 Sep;95(9):915-925
pubmed: 28547076
Purinergic Signal. 2017 Sep;13(3):363-386
pubmed: 28547381
FASEB J. 2017 Nov;31(11):4745-4758
pubmed: 28701304
Anesth Analg. 2018 Jan;126(1):308-321
pubmed: 28759485
Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L83-L92
pubmed: 28982733
Am J Respir Crit Care Med. 2018 Mar 1;197(5):549-551
pubmed: 29091746
Trials. 2017 Nov 13;18(1):536
pubmed: 29132404
Int J Mol Sci. 2018 Apr 13;19(4):null
pubmed: 29652806
Respir Res. 2018 May 28;19(1):103
pubmed: 29807526
Am J Physiol Cell Physiol. 2018 Oct 1;315(4):C558-C570
pubmed: 29898376
Front Physiol. 2018 Jun 01;9:555
pubmed: 29910735
COPD. 2018 Dec;15(6):559-571
pubmed: 30663435
Nat Rev Dis Primers. 2019 Mar 14;5(1):18
pubmed: 30872586
J Appl Physiol (1985). 1986 Nov;61(5):1667-76
pubmed: 3536837
Br J Clin Pharmacol. 1983 Feb;15(2):161-5
pubmed: 6303374
Science. 1993 Jul 23;261(5120):466-9
pubmed: 8101391
Am Rev Respir Dis. 1993 Jul;148(1):91-7
pubmed: 8317821
Am Rev Respir Dis. 1993 Mar;147(3):553-8
pubmed: 8442586
J Clin Invest. 1998 Jan 15;101(2):295-300
pubmed: 9435300

Auteurs

Thanh-Thuy T Le (TT)

Department of Anesthesiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.

Nathaniel K Berg (NK)

Department of Anesthesiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.

Matthew T Harting (MT)

Department of Pediatric Surgery, McGovern Medical School, Children's Memorial Hermann Hospital, The University of Texas Health Science Center at Houston, Houston, TX, United States.

Xiangyun Li (X)

Department of Anesthesiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.
Department of Anesthesiology, Tianjin Nankai Hospital, Tianjin Medical University, Tianjin, China.

Holger K Eltzschig (HK)

Department of Anesthesiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.

Xiaoyi Yuan (X)

Department of Anesthesiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH